Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

### China Medical and Bio Science Limited

(Provisional Liquidators Appointed)

## 中華藥業生物科學有限公司\*

(已委任臨時清盤人)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8120)

# ADJOURNMENT OF THE BOARD MEETING AND

### DELAY IN PUBLICATIONS OF INTERIM RESULTS AND INTERIM REPORT FOR THE SIX MONTHS ENDED 31 JANUARY 2011

The Provisional Liquidators and the Directors announce that the board meeting in relation to the interim results of the Group will be adjourned until further notice. It is expected that the Interim Results and the Interim Report will be published on or before 31 March 2011.

The delay in the publications of the Interim Results and the Interim Report constitute breaches of Rules 18.53 and 18.78 of the GEM Listing Rules.

Reference is made to the notice of board meeting of China Medical and Bio Science Limited (Provisional Liquidators Appointed) (the "Company") dated 7 March 2011 (the "Notice"). Reference is also made to the announcement of the Company dated 3 August 2009 (the "Announcement") in relation to the exclusivity agreement entered into amongst NEUF Capital Limited, the Company and the Provisional Liquidators on 28 July 2009. Unless otherwise stated, terms used herein shall have the same meanings as those defined in the Notice and the Announcement.

The Provisional Liquidators and the directors of the Company (the "**Directors**") announce that the board meeting referred in the Notice will be adjourned until further notice because the Company requires additional time to complete the preparation of the consolidated financial statements of the Company for the six months ended 31 January 2011. The Company also wishes to announce that pursuant to the terms of the Exclusivity Agreement, the Exclusivity Period has expired on 27 January 2011. The Company and the Provisional Liquidators are currently reviewing the situation with a view to continuing with the Resumption Proposal.

It is expected that the publications of the announcement of the interim results of the Group (the "Interim Results") and the interim report of the Company (the "Interim Report") for the six months ended 31 January 2011 shall have to be delayed. It is expected that the Interim Results and the Interim Report will be published on or before 31 March 2011.

The delay in the publications of the Interim Results and the Interim Report constitute breaches of Rules 18.53 and 18.78 of the GEM Listing Rules. The Stock Exchange reserves the right to take appropriate actions against the Company and/or the Directors in respect of such breaches.

#### SUSPENSION OF TRADING

Trading in the shares of the Company has been suspended since 9:30 a.m. on 28 October 2008 at the request of the Company and will remain suspended until further notice.

For and on behalf of

China Medical and Bio Science Limited
(Provisional Liquidators Appointed)

Fork Siu Kee, Thomas

Company Secretary

Hong Kong, 17 March 2011

As at the date of this announcement, the Board comprises two executive Directors, namely Ms. Wong Moon Ha and Mr. Wong Sai Wa.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will appear on the GEM website (www.hkgem.com) for at least seven days after the date of publication and on the website of the Company at www.irasia.com/listco/hk/chinamedical.

\* For identification purpose only